Previous close | 1.0600 |
Open | 1.0800 |
Bid | 1.2800 x 1300 |
Ask | 1.2700 x 1000 |
Day's range | 1.0700 - 1.5400 |
52-week range | 1.0300 - 40.2100 |
Volume | |
Avg. volume | 820,855 |
Market cap | 50.379M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.4630 |
Earnings date | 10 Aug 2022 - 15 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SAN JOSE, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR) (the “Company” or “Eargo”), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced the Company received a letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that because it remains delinquent in filing its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 and its Annual Report on Form 10-K for th
Reached settlement agreement to resolve DOJ investigation Company to Hold Conference Call and Web Cast on May 2, 2022 at 8 a.m. Eastern Time SAN JOSE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR) (the “Company”), a medical device company on a mission to improve the quality of life of people with hearing loss, today provided a business update and provided guidance on its operating cash runway. Business Updates: Preliminary first quarter 2022 Gross systems shipped is expect
SAN JOSE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR) (“Eargo” or the “Company”) has entered into a civil settlement agreement with the United States to resolve the previously disclosed investigation by the U.S. Department of Justice (the “DOJ”) related to insurance reimbursement claims submitted to various federal employee health plans under the Federal Employee Health Benefits (“FEHB”) program. Eargo fully cooperated with the DOJ’s investigation, the resolution of whic